AI Article Synopsis

  • The study aimed to evaluate the impact of injecting bone marrow aspirate concentrate (BMAC) into the hip joint during arthroscopy for patients with symptomatic labral tears and early degenerative changes.
  • A comparison was made between 35 patients who received BMAC injections and 35 control patients, with similar demographics, to assess various patient-reported outcomes (PROs) over two years post-surgery.
  • Results showed significant improvements in PROs for both groups, although the BMAC group had a higher failure rate leading to total hip arthroplasty, and no significant difference was found in outcomes between the two groups.

Article Abstract

Purpose: To define the clinical effect of intra-articular injection of iliac crest-derived bone marrow aspirate concentrate (BMAC) at the time of hip arthroscopy in patients with symptomatic labral tears and early radiographic degenerative changes.

Methods: A retrospective review of a prospectively collected hip registry database was performed. Patients with symptomatic labral tears and Tönnis grade 1 or 2 degenerative changes who underwent labrum-preserving hip arthroscopy with BMAC injection were included and were matched with patients who underwent hip arthroscopy without BMAC injection. Patient-reported outcomes (PROs) collected preoperatively and up to 2 years postoperatively included the modified Harris Hip Score, Hip Outcome Score-Activities of Daily Living, Hip Outcome Score-Sport, and International Hip Outcome Tool 33 score. Clinical relevance was measured with the minimal clinically important difference, patient acceptable symptom state, and substantial clinical benefit for each outcome score.

Results: A total of 35 patients underwent labrum-preserving hip arthroscopy with BMAC injection and were matched with 35 control patients. There were no differences in demographic characteristics between the groups (P > .05). The BMAC group consisted of 22 patients (62.9%) with Tönnis grade 1 changes and 13 (37.1%) with Tönnis grade 2 changes, whereas all 35 control patients had Tönnis grade 0 hips. All PROs were significantly improved in both groups at 2 years, with no difference in improvement. The rate of failure requiring conversion to total hip arthroplasty was 14.3% (mean, 1.6 years postoperatively) in the BMAC group and 5.7% (mean, 7 years postoperatively) in the control group (P = .09). The difference in the frequency of patients achieving the minimal clinically important difference, patient acceptable symptom state, and substantial clinical benefit was not statistically significant between cohorts.

Conclusions: In a challenging group of patients with symptomatic labral tears and early radiographic degenerative changes, hip arthroscopy with BMAC injection results in statistically and clinically significant improvement in PROs comparable to a group of patients with nonarthritic hips undergoing hip arthroscopy at short-term follow-up.

Level Of Evidence: Level III, retrospective comparative therapeutic trial.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.arthro.2022.12.012DOI Listing

Publication Analysis

Top Keywords

hip arthroscopy
32
symptomatic labral
20
labral tears
20
patients symptomatic
16
tönnis grade
16
arthroscopy bmac
16
bmac injection
16
hip
14
patients
12
tears early
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!